These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 9662049)

  • 1. Differential expression of receptors for advanced glycation end products on monocytes in patients with IDDM.
    Festa A; Schmölzer B; Schernthaner G; Menzel EJ
    Diabetologia; 1998 Jun; 41(6):674-80. PubMed ID: 9662049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of long-term glycated low density lipoprotein and AGE-albumin by peripheral monocytes and endothelial cells.
    Sobal G; Sinzinger H; Menzel EJ
    J Recept Signal Transduct Res; 1999; 19(1-4):267-81. PubMed ID: 10071763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation--are they inter-related?
    Sebeková K; Podracká L; Heidland A; Schinzel R
    Clin Nephrol; 2001 Dec; 56(6):S21-6. PubMed ID: 11770807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The induction of surface beta-amyloid binding proteins and enhanced cytotoxicity in cultured PC-12 and IMR-32 cells by advanced glycation end products.
    Mruthinti S; Sood A; Humphrey CL; Swamy-Mruthinti S; Buccafusco JJ
    Neuroscience; 2006 Oct; 142(2):463-73. PubMed ID: 16890367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced glycation end products subspecies-selectively induce adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells.
    Takahashi HK; Mori S; Wake H; Liu K; Yoshino T; Ohashi K; Tanaka N; Shikata K; Makino H; Nishibori M
    J Pharmacol Exp Ther; 2009 Jul; 330(1):89-98. PubMed ID: 19380603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E; Piperi C; Kalofoutis A; Creatsas G
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):37-43. PubMed ID: 15638868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Diabetes Metab Res Rev; 2008 Feb; 24(2):109-14. PubMed ID: 17694504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum levels of advanced glycation end products and their monocyte receptors in patients with type 2 diabetes.
    Su XD; Li SS; Tian YQ; Zhang ZY; Zhang GZ; Wang LX
    Arch Med Res; 2011 Oct; 42(7):596-601. PubMed ID: 22100610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs.
    Thornalley PJ
    Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1013-23. PubMed ID: 9846883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.
    Soulis T; Thallas V; Youssef S; Gilbert RE; McWilliam BG; Murray-McIntosh RP; Cooper ME
    Diabetologia; 1997 Jun; 40(6):619-28. PubMed ID: 9222639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells.
    Stitt AW; He C; Vlassara H
    Biochem Biophys Res Commun; 1999 Mar; 256(3):549-56. PubMed ID: 10080935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of CD36 protein expression by AGEs and insulin in aortic VSMCs from diabetic and non-diabetic rats.
    de Oliveira Silva C; Delbosc S; Araïs C; Monnier L; Cristol JP; Pares-Herbute N
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):23-30. PubMed ID: 17127041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages.
    Iwashima Y; Eto M; Hata A; Kaku K; Horiuchi S; Ushikubi F; Sano H
    Biochem Biophys Res Commun; 2000 Oct; 277(2):368-80. PubMed ID: 11032732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin E2 inhibits advanced glycation end product-induced adhesion molecule expression on monocytes, cytokine production, and lymphocyte proliferation during human mixed lymphocyte reaction.
    Takahashi HK; Zhang J; Mori S; Liu K; Wake H; Liu R; Sadamori H; Matsuda H; Yagi T; Yoshino T; Nishibori M
    J Pharmacol Exp Ther; 2010 Sep; 334(3):964-72. PubMed ID: 20558773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor of advanced glycation end products (RAGE) positively regulates CD36 expression and reactive oxygen species production in human monocytes in diabetes.
    Xanthis A; Hatzitolios A; Fidani S; Befani C; Giannakoulas G; Koliakos G
    Angiology; 2009 Dec-2010 Jan; 60(6):772-9. PubMed ID: 19190027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced glycation end products in diabetic patients with optimized glycaemic control and their effects on endothelial reactivity: possible implications in venous graft failure.
    Chello M; Spadaccio C; Lusini M; Covino E; Blarzino C; De Marco F; Di Domenico F; Coccia R
    Diabetes Metab Res Rev; 2009 Jul; 25(5):420-6. PubMed ID: 19405075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy.
    Stitt AW; Moore JE; Sharkey JA; Murphy G; Simpson DA; Bucala R; Vlassara H; Archer DB
    Invest Ophthalmol Vis Sci; 1998 Dec; 39(13):2517-23. PubMed ID: 9856760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AGE down-regulation of monocyte RAGE expression and its association with diabetic complications in type 1 diabetes.
    Miura J; Uchigata Y; Yamamoto Y; Takeuchi M; Sakurai S; Watanabe T; Yonekura H; Yamagishi S; Makita Z; Sato A; Omori Y; Yamamoto H; Iwamoto Y
    J Diabetes Complications; 2004; 18(1):53-9. PubMed ID: 15019601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
    Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
    Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.